Short answer
Intellia Therapeutics, Inc. (NTLA) filed an 8-K current report with the SEC on February 26, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q4 and full-year 2025 earnings announced Feb 26, 2026; full results in Exhibit 99.1.
Intellia Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q4 and full-year 2025 earnings announced Feb 26, 2026; full results in Exhibit 99.1
- NTLA is a clinical-stage gene editing company: revenue and cash runway are key metrics to watch in the release
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Intellia Therapeutics, Inc. 8-K filings
Get the next NTLA 8-K as it lands
Follow NTLA for push alerts, or ask the research agent what this filing means.